Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial.
Rachel A WarrenAllie S CarewPantelis AndreouChristine HermanAndrew P LevyHenry N GinsbergJohn SappEric B RimmSusan KirklandLeah E CahillPublished in: Diabetes care (2021)
The effect of fenofibrate added to simvastatin on risk of CAD events depends on Hp phenotype in the ACCORD lipid trial.